Podcast Sponsor: Addgene - Today’s Podcast is sponsored by Addgene, a non-profit organization facilitating biomedical research by operating a library for published and useful plasmids. Find out more at www.addgene.org
Susan Molineaux, CEO, Calithera Bio and Contact Info
Chapters: (Advance the marker)
1:17 Is Calithera the ideal model for drug discovery and development?
2:09 With virtual model, "scientists have no skin in the game"
12:29 $40 million the right number
14:38 Success at Proteolix - "there's nothing like helping patients"
19:45 What is "negative persistence?"
23:27 "I grew up thinking math and science were great. There was no gender barrier."
29:16 "I didn't raise my hand and say I just need to manage."
33:40 When did you say I'm going to found a biotech company?
38:39 Why is mentorship important?
41:40 Thoughts on Affordable Care Act
Susan Molineaux thrives on the knowledge that what she does each day is making a difference in the lives of patients. CEO and founder of Calithera BioSciences, a start-up biotech housed in the same building with Crescendo Biosciences in South San Francisco, Molineaux knows the taste of success. Previously she led Proteolix in the development of cafilzomib, a therapeutic for multiple myeloma patients. Proteolix was bought out by Onyx Pharmaceuticals during late stage trials for a hefty sum. The purchase is paying off for Onyx as they just received FDA approval for the drug and saw their stock take a big jump.
Susan says her success comes from an early grounding in science that was free from gender barriers. She's a speaker at many conferences around the Bay Area and mentors for local entrepreneurs and students. Susan talks about what she's doing at Calithera and weighs in on what could be a better model for drug development.